Skip to content

Riluzole

Exservan, Rilutek, Tiglutik, Riluzole Zentiva (riluzole) is a small molecule pharmaceutical. Riluzole was first approved as Exservan on 1995-12-12. It is used to treat amyotrophic lateral sclerosis in the USA. It has been approved in Europe to treat amyotrophic lateral sclerosis. It is known to target potassium channel subfamily K member 4, intermediate conductance calcium-activated potassium channel protein 4, potassium channel subfamily K member 2, potassium voltage-gated channel subfamily H member 2, short transient receptor potential channel 5, small conductance calcium-activated potassium channel protein 3, potassium voltage-gated channel subfamily D member 2, small conductance calcium-activated potassium channel protein 1, small conductance calcium-activated potassium channel protein 2, potassium voltage-gated channel subfamily D member 3, and calmodulin-1. Riluzole's patents are valid until 2029-03-12 (FDA).
Trade Name Rilutek, Riluzole Zentiva
Common Name Riluzole
Indication amyotrophic lateral sclerosis
Drug Class
Riluzole
Get full access now